Press coverage about CareDx (NASDAQ:CDNA) has been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a daily sentiment score of 0.29 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.4252116269409 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages have commented on CDNA. ValuEngine upgraded shares of CareDx from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of CareDx in a report on Wednesday, January 31st. Finally, Zacks Investment Research upgraded shares of CareDx from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Wednesday, January 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $8.65.
Shares of CDNA stock traded up $0.29 during mid-day trading on Wednesday, reaching $6.06. 244,581 shares of the company’s stock were exchanged, compared to its average volume of 224,092. The company has a current ratio of 0.55, a quick ratio of 0.35 and a debt-to-equity ratio of -124.53. CareDx has a 52-week low of $0.76 and a 52-week high of $7.98.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.